FBXO7 Antibody

說明書

中文名稱：

FBXO7兔多克隆抗體
貨號：

CSB-PA667562ESR2HU
規(guī)格：

￥440
圖片：
Western blot
All lanes: FBXO7 antibody at 3.97µg/ml
Lane 1: Mouse gonadal tissue
Lane 2: Jurkat whole cell lysate
Lane 3: 293T whole cell lysate
Lane 4: PC-3 whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 59, 50, 46 kDa
Observed band size: 59 kDa

Immunohistochemistry of paraffin-embedded human testis tissue using CSB-PA667562ESR2HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human prostate cancer using CSB-PA667562ESR2HU at dilution of 1:100
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) FBXO7 Polyclonal antibody
Uniprot No.：

Q9Y3I1
基因名：

FBXO7
別名：

F box only protein 7 antibody; F box protein 7 antibody; F-box only protein 7 antibody; FBX antibody; FBX07 antibody; FBX7 antibody; FBX7_HUMAN antibody; Fbxo7 antibody; PARK15 antibody; PKPS antibody
宿主：

Rabbit
反應(yīng)種屬：

Human, Mouse
免疫原：

Recombinant Human F-box only protein 7 protein (353-522AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes BIRC2 and DLGAP5. Plays a role downstream of PINK1 in the clearance of damaged mitochondria via selective autophagy (mitophagy) by targeting PRKN to dysfunctional depolarized mitochondria. Promotes MFN1 ubiquitination.
基因功能參考文獻：
1. Fbxo7 deficiency is associated with reduced cellular NAD(+) levels, which results in increased mitochondrial NADH redox index and impaired activity of complex I in the electron transport chain. PMID: 27689878
2. Structure and function of Fbxo7 in Parkinson's disease has been summarized. (Review) PMID: 26965690
3. Gsk3beta and Tomm20 are substrates of the SCFFbxo7/PARK15 ubiquitin ligase associated with Parkinson's disease PMID: 27503909
4. Mutations in the F-box only protein 7 (FBXO7) gene, located on chromosome 22q12-q13, have been identified as having distinct clinical features in patients with hereditary Parkinson's disease (PD). PMID: 26882974
5. The mutations of F-box protein 7 (FBXO7) gene (T22M, R378G and R498X) are associated with autosomal recessive juvenile-onset Parkinson's disease We demonstrated wild-type FBXO7 is a stress response protein with both cytoprotective and neurotoxic roles PMID: 26310625
6. This is first time a FBXO7 mutation has been identified that causes phenotype compatible with typical idiopathic Parkinson's disease and presents with some of its common nonmotor features PMID: 26010069
7. High expression of PARK15 might lead to the occurrence of non-small-cell lung cancer. PMID: 26245297
8. genetic analysis of this Turkish family and the Italian PARK15 family reported previously revealed that the c.1492C > T mutation is present on two different haplotypes in the Italian family PMID: 25085748
9. in addition to the parkinsonian-pyramidal phenotype, in connection with FBXO7 mutations and points to an intrafamilial phenotypic variation PMID: 25169713
10. Cys52 variant of FBXO7 may contribute to reduced Parkinson's disease susceptibility in Chinese PMID: 25029497
11. The involvement of the FBXO7 gene in PD is very rare, at least in this population from southern Spain. PMID: 24112787
12. The crystal structure of the Fbxo7 FP domain is reported at 2.0 A resolution. The Fbxo7 FP domain adopts an alpha/beta-fold similar to that of the PI31 FP domain. PMID: 24419388
13. A mutational analysis of the FBXO7 gene in Taiwanese patients with Parkinson's disease (PD) does not show a potential pathophysiological role in PD. PMID: 23352116
14. This study showed that Fbxo7 participates in mitochondrial maintenance through direct interaction with PINK1 and Parkin and acts in Parkin-mediated mitophagy. PMID: 23933751
15. An important role is suggested for FBXO7 in the pathogenesis of synucleinopathies, including Parkinson's disease and multiple system atrophy. PMID: 23656991
16. Mutations in FBX07 is often associated with rapidly progressive parkinsonism and with additional features including pyramidal signs, cognitive decline and loss of sustained Levodopa responsiveness. PMID: 23196729
17. analysis of the zebrafish model of Fbxo7 mutations with a role in levodopa-responsive parkinsonism with severe loss of nigrostriatal dopaminergic neurons PMID: 23133663
18. [review] PARK15-associated parkinsonism, also referred to as parkinsonian-pyramidal disease (PPD), is caused by mutations in the F-box only protein 7 gene FBXO7. PMID: 23318512
19. FBXO7 is a negative regulator of NF-KB signalling, modulating ubiquitination of several components of the TNF-R1 signalling complex and ultimately lowering NF-KB signalling activity. PMID: 22212761
20. activity of FBXO7 in the nucleus appears therefore crucial for the maintenance of brain neurons and the pathogenesis of PARK15 PMID: 21347293
21. Fbxo7 negatively regulates the proliferation and differentiation of haematopoietic progenitor cells in a p53-dependent manner PMID: 21695055
22. Skp1 binding prevented Fbxo7 from contacting CRM1. PMID: 21378169
23. We identified genetic deficits in FBXO7 that were associated with Levodopa responsive parkinsonism with pyramidal signs. PMID: 20669327
24. FBXO7 mutations may be rare in Chinese early-onset Parkinsonism patients. PMID: 20603184
25. Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region PMID: 15145941
26. a model for FP domain-mediated dimerization of SCF(Fbxo7) and PI31 PMID: 18495667
27. Recessive FBXO7 mutations cause progressive neurodegeneration with extrapyramidal and pyramidal system involvement, delineating a novel genetically defined entity that we propose to designate as PARK15. PMID: 19038853
顯示更多

收起更多
相關(guān)疾病：

Parkinson disease 15 (PARK15)
亞細(xì)胞定位：

Cytoplasm. Nucleus. Mitochondrion. Cytoplasm, cytosol.
數(shù)據(jù)庫鏈接：

HGNC: 13586

OMIM: 260300

KEGG: hsa:25793

STRING: 9606.ENSP00000266087

UniGene: Hs.5912

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human